Keyphrases
Atrial Fibrillation
100%
Stable Coronary Artery Disease
69%
Liraglutide
60%
Confidence Interval
48%
Hazard Ratio
48%
Coronary Artery Disease
45%
Middle-aged
45%
All-cause Mortality
40%
Patients with Coronary Artery Disease
34%
Placebo-controlled
33%
Population-based
32%
Randomized Double-blind
31%
Type 2 Diabetes Mellitus (T2DM)
31%
Exome
30%
Community-dwelling
30%
Hypokalemia
30%
Glucagon-like
29%
Cardiovascular Events
28%
Copenhagen
28%
Placebo
25%
Incident Atrial Fibrillation
24%
Ectopic Activity
24%
New-onset Type 2 Diabetes
22%
Genetic Variants
22%
Early Onset
21%
Clarithromycin
21%
Heart Rate
20%
Metformin
20%
Pathogenicity
20%
New Population
20%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
20%
Cardiovascular Risk
19%
A1 Receptor
17%
Receptor Agonist
17%
Arrhythmia
17%
Type 2 Diabetic Patients
17%
Composite Outcome
16%
Stroke Risk
16%
Heart Rate Variability
15%
Risk Factors
15%
Lone Atrial Fibrillation
15%
Pharmacology, Toxicology and Pharmaceutical Science
Coronary Artery Disease
82%
Placebo
54%
Liraglutide
50%
Non Insulin Dependent Diabetes Mellitus
43%
Ischemic Heart Disease
41%
Cohort Study
41%
Cerebrovascular Accident
38%
All Cause Mortality
36%
Atrial Fibrillation
33%
Hypokalemia
30%
Cardiovascular Risk
27%
Brain Natriuretic Peptide
22%
Long Term Exposure
21%
Isotopes of Potassium
21%
Clarithromycin
21%
Troponin T
21%
Glucagon Like Peptide 1 Receptor Agonist
16%
Obesity
15%
Medicine and Dentistry
Coronary Artery Disease
52%
Atrial Fibrillation
47%
Apoplexy
46%
Liraglutide
40%
Hazard Ratio
38%
Middle Age
33%
Maturity Onset Diabetes of the Young
30%
Placebo
28%
Blood Pressure
22%
Cohort Analysis
21%
Hypokalemia
20%
All Cause Mortality
17%
Patient with Type 2 Diabetes
16%
